Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands

The Netherlands is a country highly affected by the COVID-19 pandemic. In this study, Slot, Hogema and colleagues report a low SARS-CoV-2 seroprevalence one month into the outbreak and provide insights into virus exposure by region and age group when widespread non-pharmaceutical interventions are i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ed Slot, Boris M. Hogema, Chantal B. E. M. Reusken, Johan H. Reimerink, Michel Molier, Jan H. M. Karregat, Johan IJlst, Věra M. J. Novotný, René A. W. van Lier, Hans L. Zaaijer
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/863a9c58df364edcbc4a6ef24499c75d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:863a9c58df364edcbc4a6ef24499c75d
record_format	dspace
spelling	oai:doaj.org-article:863a9c58df364edcbc4a6ef24499c75d2021-12-02T17:32:12ZLow SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands10.1038/s41467-020-19481-72041-1723https://doaj.org/article/863a9c58df364edcbc4a6ef24499c75d2020-11-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-19481-7https://doaj.org/toc/2041-1723The Netherlands is a country highly affected by the COVID-19 pandemic. In this study, Slot, Hogema and colleagues report a low SARS-CoV-2 seroprevalence one month into the outbreak and provide insights into virus exposure by region and age group when widespread non-pharmaceutical interventions are in place.Ed SlotBoris M. HogemaChantal B. E. M. ReuskenJohan H. ReimerinkMichel MolierJan H. M. KarregatJohan IJlstVěra M. J. NovotnýRené A. W. van LierHans L. ZaaijerNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-7 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Ed Slot Boris M. Hogema Chantal B. E. M. Reusken Johan H. Reimerink Michel Molier Jan H. M. Karregat Johan IJlst Věra M. J. Novotný René A. W. van Lier Hans L. Zaaijer Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands
description	The Netherlands is a country highly affected by the COVID-19 pandemic. In this study, Slot, Hogema and colleagues report a low SARS-CoV-2 seroprevalence one month into the outbreak and provide insights into virus exposure by region and age group when widespread non-pharmaceutical interventions are in place.
format	article
author	Ed Slot Boris M. Hogema Chantal B. E. M. Reusken Johan H. Reimerink Michel Molier Jan H. M. Karregat Johan IJlst Věra M. J. Novotný René A. W. van Lier Hans L. Zaaijer
author_facet	Ed Slot Boris M. Hogema Chantal B. E. M. Reusken Johan H. Reimerink Michel Molier Jan H. M. Karregat Johan IJlst Věra M. J. Novotný René A. W. van Lier Hans L. Zaaijer
author_sort	Ed Slot
title	Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands
title_short	Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands
title_full	Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands
title_fullStr	Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands
title_full_unstemmed	Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands
title_sort	low sars-cov-2 seroprevalence in blood donors in the early covid-19 epidemic in the netherlands
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/863a9c58df364edcbc4a6ef24499c75d
work_keys_str_mv	AT edslot lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands AT borismhogema lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands AT chantalbemreusken lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands AT johanhreimerink lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands AT michelmolier lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands AT janhmkarregat lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands AT johanijlst lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands AT veramjnovotny lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands AT reneawvanlier lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands AT hanslzaaijer lowsarscov2seroprevalenceinblooddonorsintheearlycovid19epidemicinthenetherlands
_version_	1718380380864643072

Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands

Ejemplares similares